Neuphoria Therapeutics Inc. (NEUP)
NASDAQ: NEUP · Real-Time Price · USD
18.37
-0.40 (-2.13%)
At close: Oct 8, 2025, 4:00 PM EDT
19.22
+0.85 (4.63%)
After-hours: Oct 8, 2025, 5:30 PM EDT

Company Description

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia.

Its lead product candidate includes BNC210, a selective negative allosteric modulator of the α7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder.

The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105 for the treatment of cancer.

In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; and Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders.

The company has a collaboration with Merck & Co., Inc. to develop α7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer’s disease and other central nervous system conditions.

The company was formerly known as Bionomics Limited and changed its name Neuphoria Therapeutics Inc. in December 2024.

Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Burlington, Massachusetts.

Neuphoria Therapeutics Inc.
Neuphoria Therapeutics logo
CountryUnited States
Founded1996
IndustryBiotechnology
SectorHealthcare
Employees24
CEOSpyridon Papapetropoulos

Contact Details

Address:
100 Summit Drive
Burlington, Massachusetts 01803
United States
Phone781 439 5551
Websiteneuphoriatx.com

Stock Details

Ticker SymbolNEUP
ExchangeNASDAQ
Fiscal YearJuly - June
Reporting CurrencyUSD
CIK Code0001191070
ISIN NumberUS64136E1029
SIC Code2834

Key Executives

NamePosition
Dr. Spyridon Papapetropoulos M.D., Ph.D.Chief Executive Officer, President and Director
Elizabeth Doolin M.Sc.Senior Vice President of Clinical Development
Dr. Julie Kerner Ph.D.Senior Vice President of Business Operations
Dr. Mark A. Smith M.D., Ph.D.Chief Medical Officer
Adrian Hinton BEC, F.C.A.Financial Controller
Rajeev Chandra B.Com., C.A., M.B.A.Company Secretary

Latest SEC Filings

DateTypeTitle
Sep 29, 202510-KAnnual Report
Sep 23, 2025424B5Filing
Sep 16, 20258-KCurrent Report
Jul 29, 2025424B5Filing
Jul 18, 20258-KCurrent Report
May 20, 20258-KCurrent Report
May 20, 202510-QQuarterly Report
May 15, 2025NT 10-QNotification of inability to timely file Form 10-Q or 10-QSB
Feb 14, 2025SCHEDULE 13G/AFiling
Feb 14, 202510-QQuarterly Report